See more : BW LPG Limited (BWLP) Income Statement Analysis – Financial Results
Complete financial analysis of Paragon 28, Inc. (FNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paragon 28, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Imerys S.A. (IMYSF) Income Statement Analysis – Financial Results
- Eni S.p.A. (ENI.F) Income Statement Analysis – Financial Results
- EKINOPS S.A. (EKI.PA) Income Statement Analysis – Financial Results
- Xinjiang Goldwind Science & Technology Co., Ltd. (2208.HK) Income Statement Analysis – Financial Results
- Aurum Pacific (China) Group Limited (8148.HK) Income Statement Analysis – Financial Results
Paragon 28, Inc. (FNA)
About Paragon 28, Inc.
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 216.39M | 181.38M | 147.46M | 110.98M | 106.28M |
| Cost of Revenue | 51.95M | 32.46M | 28.02M | 25.10M | 18.83M |
| Gross Profit | 164.44M | 148.93M | 119.44M | 85.88M | 87.45M |
| Gross Profit Ratio | 75.99% | 82.11% | 81.00% | 77.38% | 82.28% |
| Research & Development | 30.08M | 24.65M | 16.13M | 11.17M | 10.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.02M | 159.32M | 114.09M | 72.64M | 74.44M |
| Other Expenses | 0.00 | -1.21M | -486.00K | 3.56M | -98.00K |
| Operating Expenses | 210.10M | 183.97M | 130.22M | 83.81M | 84.73M |
| Cost & Expenses | 262.05M | 216.43M | 158.24M | 108.91M | 103.56M |
| Interest Income | 0.00 | 4.13M | 1.72M | 602.00K | 648.00K |
| Interest Expense | 5.17M | 4.13M | 1.72M | 602.00K | 648.00K |
| Depreciation & Amortization | 15.54M | 13.73M | 8.96M | 6.38M | 4.20M |
| EBITDA | -36.61M | -47.86M | -2.30M | 12.01M | 6.82M |
| EBITDA Ratio | -16.92% | -12.42% | -1.56% | 10.82% | 6.42% |
| Operating Income | -45.67M | -35.05M | -10.78M | 5.63M | 2.72M |
| Operating Income Ratio | -21.10% | -19.32% | -7.31% | 5.07% | 2.56% |
| Total Other Income/Expenses | -11.66M | -5.34M | -2.21M | 2.96M | -746.00K |
| Income Before Tax | -57.32M | -67.39M | -12.98M | 5.03M | 1.97M |
| Income Before Tax Ratio | -26.49% | -37.15% | -8.80% | 4.53% | 1.85% |
| Income Tax Expense | 213.00K | -64.00K | 713.00K | 1.53M | -1.15M |
| Net Income | -57.53M | -67.33M | -13.69M | 2.69M | 3.12M |
| Net Income Ratio | -26.59% | -37.12% | -9.29% | 2.42% | 2.93% |
| EPS | -0.70 | -0.88 | -0.18 | 0.04 | 0.04 |
| EPS Diluted | -0.70 | -0.88 | -0.18 | 0.04 | 0.04 |
| Weighted Avg Shares Out | 82.09M | 76.77M | 76.45M | 76.37M | 76.37M |
| Weighted Avg Shares Out (Dil) | 82.09M | 76.77M | 76.45M | 76.37M | 76.37M |
FNA Deadline: FNA Investors with Losses in Excess of $100K Have Opportunity to Lead Paragon 28, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
FINAL REMINDER FNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Paragon 28, Inc. Investors to Participate in the Class Action Lawsuit
FNA LAWSUIT ALERT: Levi & Korsinsky Notifies Paragon 28, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Class Action Filed Against Paragon 28, Inc. (FNA) - November 29, 2024 Deadline to Join - Contact Levi & Korsinsky
Levi & Korsinsky Reminds Paragon 28, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 29, 2024 - FNA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 29, 2024 in Paragon 28, Inc. Lawsuit - FNA
DEADLINE TOMORROW: Shareholders With Losses Are Urged To Join The Schall Law Firm In A Securities Fraud Case Against Paragon 28 Inc
FNA Investors Have Opportunity to Lead Paragon 28, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Paragon 28, Inc. (FNA) Shareholders
FINAL FNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Paragon 28, Inc. Investors to Join the Class Action Lawsuit
Source: https://incomestatements.info
Category: Stock Reports